Cargando…

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity

CONTEXT: Bacillus Calmette-Guerin (BCG) therapy is the standard treatment for nonmuscle-invasive bladder cancer (NMIBC). However, its toxicity is a major concern. AIM: If we reduce the number of BCG doses by half and replace the second half with epirubicin, we may have a lower toxicity while maintai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali-El-Dein, Bedeir, Barakat, Tamer S., Nabeeh, Adel, Ibrahiem, El-Housseiny I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685738/
https://www.ncbi.nlm.nih.gov/pubmed/23798868
http://dx.doi.org/10.4103/0974-7796.110008
_version_ 1782273727204950016
author Ali-El-Dein, Bedeir
Barakat, Tamer S.
Nabeeh, Adel
Ibrahiem, El-Housseiny I.
author_facet Ali-El-Dein, Bedeir
Barakat, Tamer S.
Nabeeh, Adel
Ibrahiem, El-Housseiny I.
author_sort Ali-El-Dein, Bedeir
collection PubMed
description CONTEXT: Bacillus Calmette-Guerin (BCG) therapy is the standard treatment for nonmuscle-invasive bladder cancer (NMIBC). However, its toxicity is a major concern. AIM: If we reduce the number of BCG doses by half and replace the second half with epirubicin, we may have a lower toxicity while maintaining the same efficacy of BCG. To test this hypothesis, we conducted this study as an update of our previous report. SETTING AND DESIGN: The study included 607 patients with Ta and T1 NMIBC between January 1994 and December 2008. MATERIALS AND METHODS: After transurethral resection of bladder tumor (TURBT), the patients received weekly doses of 120 mg BCG alternating with 50 mg epirubicin for six weeks (three weekly doses of each). Maintenance was given. Recurrence, progression rates, and toxicity were assessed. End points were progression, recurrence, and cancer-specific survival. RESULTS: A total of 532 patients were eligible for evaluation (mean age: 58 years; median follow-up: 45 months). Of these, 291 (55%) were free, 157 (29.5%) showed recurrence, and 84 (15.8%) showed muscle-invasive progression. Toxicity developed in 221 patients. These were mild in the majority (167), whereas 10 developed hematuria, 30 severe cystitis, and five systemic complications. The rate of permanent therapy discontinuation was 3.8%. STATISTICAL ANALYSIS USED: SPSS package version 16 and Kaplan-Meier curves were used to evaluate survival. CONCLUSIONS: Reducing the frequency of BCG instillations by half and replacing the second half with epirubicin results in a similar efficacy and a lower toxicity compared with historical cases receiving BCG alone. However, further trials are required to support these results.
format Online
Article
Text
id pubmed-3685738
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36857382013-06-24 Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity Ali-El-Dein, Bedeir Barakat, Tamer S. Nabeeh, Adel Ibrahiem, El-Housseiny I. Urol Ann Original Article CONTEXT: Bacillus Calmette-Guerin (BCG) therapy is the standard treatment for nonmuscle-invasive bladder cancer (NMIBC). However, its toxicity is a major concern. AIM: If we reduce the number of BCG doses by half and replace the second half with epirubicin, we may have a lower toxicity while maintaining the same efficacy of BCG. To test this hypothesis, we conducted this study as an update of our previous report. SETTING AND DESIGN: The study included 607 patients with Ta and T1 NMIBC between January 1994 and December 2008. MATERIALS AND METHODS: After transurethral resection of bladder tumor (TURBT), the patients received weekly doses of 120 mg BCG alternating with 50 mg epirubicin for six weeks (three weekly doses of each). Maintenance was given. Recurrence, progression rates, and toxicity were assessed. End points were progression, recurrence, and cancer-specific survival. RESULTS: A total of 532 patients were eligible for evaluation (mean age: 58 years; median follow-up: 45 months). Of these, 291 (55%) were free, 157 (29.5%) showed recurrence, and 84 (15.8%) showed muscle-invasive progression. Toxicity developed in 221 patients. These were mild in the majority (167), whereas 10 developed hematuria, 30 severe cystitis, and five systemic complications. The rate of permanent therapy discontinuation was 3.8%. STATISTICAL ANALYSIS USED: SPSS package version 16 and Kaplan-Meier curves were used to evaluate survival. CONCLUSIONS: Reducing the frequency of BCG instillations by half and replacing the second half with epirubicin results in a similar efficacy and a lower toxicity compared with historical cases receiving BCG alone. However, further trials are required to support these results. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3685738/ /pubmed/23798868 http://dx.doi.org/10.4103/0974-7796.110008 Text en Copyright: © Urology Annals http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ali-El-Dein, Bedeir
Barakat, Tamer S.
Nabeeh, Adel
Ibrahiem, El-Housseiny I.
Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title_full Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title_fullStr Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title_full_unstemmed Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title_short Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
title_sort weekly intravesical bacillus calmette-guerin (bcg) alternating with epirubicin in ta and t1 urothelial bladder cancer: an approach to decrease bcg toxicity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685738/
https://www.ncbi.nlm.nih.gov/pubmed/23798868
http://dx.doi.org/10.4103/0974-7796.110008
work_keys_str_mv AT alieldeinbedeir weeklyintravesicalbacilluscalmetteguerinbcgalternatingwithepirubicinintaandt1urothelialbladdercanceranapproachtodecreasebcgtoxicity
AT barakattamers weeklyintravesicalbacilluscalmetteguerinbcgalternatingwithepirubicinintaandt1urothelialbladdercanceranapproachtodecreasebcgtoxicity
AT nabeehadel weeklyintravesicalbacilluscalmetteguerinbcgalternatingwithepirubicinintaandt1urothelialbladdercanceranapproachtodecreasebcgtoxicity
AT ibrahiemelhousseinyi weeklyintravesicalbacilluscalmetteguerinbcgalternatingwithepirubicinintaandt1urothelialbladdercanceranapproachtodecreasebcgtoxicity